Contact ETF Channel Meet Our Editorial Staff. Minutes ETF data powered by Ticker Technologies, and Mergent. Video widget and ETF videos powered by Market News Video.
#HOLDING RAPT FULL#
By visiting, using or viewing this site, youĪgree to the following Full Disclaimer & Terms of UseĪnd Privacy Policy. Liable for any loss or damage caused by your reliance on information obtained. its subsidiaries, partners, officers, employees, affiliates, or agents be held All viewers agree that under noĬircumstances will BNK Invest, Inc. RAPT Therapeutics Inc: Website: Sector: Drugs & Pharmaceuticals: Number of ETFs Holding RAPT: 22: Total Market Value Held by ETFs: 101,019,911.56: Total Market Capitalization: 1,070,000,000 of Market Cap. Transaction, or investment strategy is suitable for any specific person. None of the information contained herein constitutes a recommendation that any particular security, portfolio, now owns 1,409 shares of the company's stock valued at 45,000 after purchasing an additional 440 shares during the last quarter. or any of its affiliates, subsidiaries or partners. boosted its holdings in RAPT Therapeutics by 45.4 in the 2nd quarter. Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counselįrom, or recommendations by BNK Invest Inc.
RAPT - Key Stats (updated 1 hour, 10 minutes ago)ĭividendRank'ed Dow Transports ComponentsĮnergy Stocks You Can Buy Cheaper Than Insiders DidĬrossing Above Their 200 Day Moving AverageĬrossing Below Their 200 Day Moving AverageĮTFs Holding RAPT | RAPT Therapeutics Inc | ETF Channel | |Ĭopyright © 2009 - 2022, All Rights Reserved Co.'s main inflammation drug candidate, RPT193, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Co.'s main oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors. In trading on Friday, shares of the Invesco Dynamic Leisure and Entertainment ETF (PEJ) crossed below their 200 day moving average of 49.20, changing hands as low as 48.67 per share.
is developing selective small molecules designed to modulate the immune responses underlying these diseases. Utilizing its proprietary drug discovery and development engine, Co. RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with needs in oncology and inflammatory diseases.